NexLife vs. Found: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, NexLife is the cheaper program at $215 a month all-in versus Found's $289 — a gap of $74 a month, $888 a year, at the 10 mg maintenance basis. NexLife: $215 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $186/mo (12-month plan). Found: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front). Prepaid terms reorder things: NexLife at $186/mo (12-month plan) and Found at $169/mo (12-month plan paid up front) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, NexLife wins at $165 versus $289 all-in — $124/mo apart. NexLife: Semaglutide runs $165 a month all-in at the standing rate ($145 on intro/plan terms). Found: Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms).

Transparency

NexLife: Source-verified (verified 2026-08-05); names its pharmacy — 6 named partner pharmacies. Found: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

NexLife: none on monthly; cancel any time on monthly. Found: none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front.

The gap, compounded over time

Here is what the $74 monthly spread between these two actually buys back over a treatment course — one month, $74; six months, $444; a year, $888; two years of maintenance, $1,776. Prepaid, the board reshuffles: Found's $169 effective edges NexLife's $186 by $204/year — both locked up front, both worth a refund-terms read first. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Maintenance therapies deserve maintenance math: over two years at standing rates, NexLife bills $5,160 and Found $6,936, a spread of $1,776 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, Found's $169 effective would total $4,056 — $1,104 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: NexLife holds $215 on every rung (four-month titration: exactly $860); Found holds $289 on every rung (four-month titration: exactly $1,156). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $215 at NexLife versus $289 at Found for the 2.5 mg rung — an early edge that holds once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $2,580/year at NexLife against $3,468 at the other: $888 of annual daylight for the same molecule and dose. The committed prepayer does best at Found: $169/month effective, $2,028/year, funds up front, refund terms first.

The semaglutide board

NexLife takes the semaglutide board too at $165 versus $289 all-in — a $124/month, $1,488/year spread. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. NexLife's ranked figure is $215, with no membership to add; Found's ranked figure is $289, with no membership to add. 2 · Maintenance basis. NexLife is dose-flat, so its entry and 10 mg figures coincide; Found is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. NexLife: standing $215, prepaid $186 effective (12-month plan); Found: standing $289, prepaid $169 effective (12-month plan paid up front) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. NexLife: source-verified, read 2026-08-05; Found: third-party-reported, read 2026-08-05. 5 · Pharmacy weighed. NexLife names 6 named partner pharmacies; Found names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

NexLife: no membership — the medication figure is the billed figure; prepaid 12-month plan at $186/mo effective; cancel any time on monthly; commitment: none on monthly. Found: no membership — the medication figure is the billed figure; prepaid 12-month plan paid up front at $169/mo effective; membership recurs; prepaid terms are paid up front; commitment: none month-to-month; prepaid terms for lowest rate. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

NexLife carries source-verified pricing (last read 2026-08-05); pharmacy disclosure is its strong suit — 6 named partner pharmacies, U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named). Found carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from NexLife to Found (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: NexLife: shipping free expedited shipping included; consultation included (provider consultation plus nutrition & fitness support); async visit model. Found: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick NexLife if the $74/month tirzepatide saving is the point; the semaglutide line is cheaper here; a named pharmacy is non-negotiable for you. Pick Found if you'll prepay for the $169 effective rate; you want the insurance paperwork done for you. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included); Mochi Health at $278 (flat, $79 membership included, named pharmacy) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $2,808/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, NexLife is the cheaper tirzepatide program by $74/mo and it doesn't trade that price for opacity ; Found's case rests on insurance navigation. Both records, with dates and sources, live in the pricing database.